Navigation Links
Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:2/1/2008

CRANBURY, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York, NY on Thursday, February 7, 2008 at 11:40 am (Eastern Standard Time) at the Grand Hyatt Hotel.

The presentation will be webcast live and may be accessed by visiting Amicus' website at http://www.amicustherapeutics.com. A replay of the webcast will also be available on the Company's website until February 22, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company has completed Phase 1 clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities L
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
2. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
3. Amicus Therapeutics to Host R&D Day
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
6. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
7. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
8. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
9. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
10. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
11. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Genta,Incorporated (OTC Bulletin Board: GNTA) today announced financial results,for the ... year, the,Company has recorded significant milestones including the following:, ... -- Oral G4544 for bone disease completes single dose-trial in ... -- leading oral taxane and new clinical-stage ...
... expanded cholesterol test can help clinicians identify best treatment ... options for patients at risk of heart disease, ... announced it will be exhibiting its VAP,Cholesterol Test in booth ... 2008, the premier scientific meeting for internal,medicine. The annual meeting ...
... SHENZHEN, China, May 7 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical,International Limited ... of medical devices in China with a rapidly growing ... the,first quarter ended March 31, 2008., Highlights ... net revenues were RMB626.0 million (US$89.3 million), ...
Cached Biology Technology:Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 2Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 3Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 4Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 5Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 6Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 7Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 8Atherotech to Exhibit the VAP Test at Internal Medicine 2008 2Mindray Medical International Announces First Quarter 2008 Results 2Mindray Medical International Announces First Quarter 2008 Results 3Mindray Medical International Announces First Quarter 2008 Results 4Mindray Medical International Announces First Quarter 2008 Results 5Mindray Medical International Announces First Quarter 2008 Results 6Mindray Medical International Announces First Quarter 2008 Results 7Mindray Medical International Announces First Quarter 2008 Results 8Mindray Medical International Announces First Quarter 2008 Results 9Mindray Medical International Announces First Quarter 2008 Results 10Mindray Medical International Announces First Quarter 2008 Results 11Mindray Medical International Announces First Quarter 2008 Results 12Mindray Medical International Announces First Quarter 2008 Results 13Mindray Medical International Announces First Quarter 2008 Results 14Mindray Medical International Announces First Quarter 2008 Results 15Mindray Medical International Announces First Quarter 2008 Results 16Mindray Medical International Announces First Quarter 2008 Results 17Mindray Medical International Announces First Quarter 2008 Results 18
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
(Date:12/10/2014)... SUNNYVALE, California , December 9, 2014 /PRNewswire/ ... Integrate with ITN,s BCARD Platform ... secure, cloud-based enterprise meeting scheduling solutions for business-to-business ... International, the world leader in mobile near-field communication ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... Chicago, November 23, 2010 Results of the world,s first ... or PrEP, were released online in the New England ... iPrEx, indicated an estimated 43.8% reduction of new HIV infections ... HIV, compared to those who took a placebo pill. ...
... how biological clocks adjust to having less sunlight in the winter ... shift work. Scientists studying the daily activity cycle in plants ... process that enables the plant,s genes to respond to the times ... of daylight in between. This system helps the plant to ...
... better tool to study how cells adhere to each other. ... stick together. Different kinds of cells have different kinds of ... focus on tens of thousands of them at a time ... but not on a single molecule. Sivasankar, an Iowa State ...
Cached Biology News:AIDS drug shown to prevent HIV in multinational trial of HIV-negative gay men 2AIDS drug shown to prevent HIV in multinational trial of HIV-negative gay men 3AIDS drug shown to prevent HIV in multinational trial of HIV-negative gay men 4Iowa State, Ames Lab researcher develops new way to study single biological molecules 2Iowa State, Ames Lab researcher develops new way to study single biological molecules 3
... 5 ml of DETACHaBEAD 19 polyclonal ... CD19 (Pan B). B cells ... and released with DETACHaBEAD CD19 are ... suitable for applications such as culturing ...
This Malachite Green Phosphate Detection Kit...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
...
Biology Products: